Non-Interventional Study With Aricept® Evess

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The Aricept® Evess study is a prospective, non-comparative, non-interventional study on use of Aricept® Evess in the treatment of out-patients with AD and Vascular Dementia. The 24 week length of the study aims to collect data from a large number of patients (n= 400) on the safety and efficacy at the usual dosage of the product providing an overview of Aricept® Evess profile.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Donepezil

Criteria

Inclusion Criteria:

• Outpatients (male / female), older than 50 years.

• Patients with clinical symptoms of mild and moderate AD and Vascular Dementia.

• MMSE score between 12 - 24.

Exclusion Criteria:

• Patients with a known hypersensitivity to donepezil clorhydrat, piperidine derivatives or any of the excipients of Aricept® Evess.

• Patients with severe impaired hepatic function.

• Patients with pre-existing gastrointestinal ulcer disease.

• Patients with the history of bronchial asthma or chronic obstructive lung disease.

• Patients with the history of serious atrioventricular conduction disturbances.